Equities

Xbrane Biopharma AB

Xbrane Biopharma AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.277
  • Today's Change0.004 / 1.28%
  • Shares traded4.80m
  • 1 Year change-96.90%
  • Beta1.8887
Data delayed at least 15 minutes, as of Jun 18 2024 12:21 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

  • Revenue in SEK (TTM)190.97m
  • Net income in SEK-361.27m
  • Incorporated2008
  • Employees75.00
  • Location
    Xbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
  • Phone+46 855905600
  • Websitehttps://xbrane.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ascelia Pharma AB0.00-88.76m311.58m13.00--5.12-----2.63-2.630.001.800.00----0.00-65.17---78.39--------------0.2302------16.72------
Bactiquant A/S18.55m-19.76m345.46m----15.90--18.62-0.6358-0.63580.59710.61330.50553.672.83---53.83-41.26-62.59-47.16-6.1412.89-106.51-71.775.43-8.540.0431---0.689--7.62------
Medivir AB7.73m-96.52m348.49m10.00--1.65--45.06-1.46-1.460.10281.890.032--1.56773,300.00-40.00-28.91-47.20-34.77-888.81-467.42-1,248.18-675.96----0.0482--73.16-20.39-0.6275---47.96--
INIFY Laboratories AB3.42m-51.43m353.12m23.00--4.83--103.21-1.15-1.150.07681.640.0322.990.6608---48.10---48.10--76.42---1,503.10------0.00--------------
Magle Chemoswed Holding AB170.01m12.23m360.72m78.0029.502.2314.402.121.131.1315.7414.950.60680.4938.302,179,628.004.362.525.863.5290.5885.677.193.920.63566.350.3081--17.009.9733.07---6.34--
Herantis Pharma Oyj0.003.15m376.47m10.00132.067.08119.59--0.01260.01260.000.23440.00----0.004.31-80.466.16-104.37------------0.0073------103.00------
Lytix Biopharma AS3.93m-86.56m386.94m10.00--6.28--98.45-2.16-2.160.09811.260.0368--0.4091399,100.00-80.96-56.91-94.07-65.83-----2,202.36-771.78----0.0095---63.8263.94-56.77------
Saniona AB20.71m-83.30m432.72m23.00--15.87--20.89-1.09-1.090.26290.24510.1726--5.63900,521.80-69.41-59.16-127.89-70.15-136.88-970.05-402.20-1,483.55---3.850.71--10.19-21.0554.71---34.94--
Xbrane Biopharma AB190.97m-361.27m441.26m75.00--1.12--2.31-1.33-1.580.69780.25770.24651.34332.122,053,430.00-46.63-40.98-78.01-67.2415.43---189.18-364.401.43-31.130.3693--314.3363.42-91.10--60.02--
Bergenbio ASA513.08k-152.17m445.51m16.00--333.46--868.32-0.1849-0.18490.00030.03470.0047--0.048520,840.00-139.81-66.15-275.19-78.74-----29,658.54-11,419.44----0.00---9.00-31.4336.98------
Enzymatica AB (publ)47.29m-53.67m471.60m18.00--5.62--9.97-0.3247-0.32470.28660.48410.32691.386.48---37.11-27.36-39.16-33.9864.2565.08-113.50-66.12---23.260.2502--4.00-0.638227.57--7.02--
Mendus AB (publ)0.00-107.07m472.37m28.00--0.6023-----3.15-3.150.0015.570.00----0.00-16.09-18.84-17.35-20.21-------28,474.53----0.0348---100.00--26.78------
Lifecare ASA12.89m-34.72m473.57m32.00--5.96--36.75-0.2454-0.24540.0920.41630.1621--4.90408,943.10-43.60-40.00-49.97-45.26-----269.03-175.53----0.1812---40.8830.29-101.74------
Hamlet BioPharma AB0.00-33.41m521.28m7.00--9.01-----0.2326-0.23260.000.4530.00-------63.45-83.52-69.09-107.84------------0.00-------18.87--78.01--
Initiator Pharma A/S0.00-33.98m539.64m3.00--16.01-----0.6241-0.62410.000.63690.00----0.00-70.60-68.27-73.77-74.02------------0.00------27.95------
Data as of Jun 18 2024. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK

Institutional shareholders

5.92%Per cent of shares held by top holders
HolderShares% Held
Handelsbanken Fonder ABas of 31 May 202451.18m3.37%
Swedbank Robur Fonder ABas of 29 May 202415.20m1.00%
Teknik Innovation Norden Fonder ABas of 31 Dec 202213.70m0.90%
SEB Investment Management ABas of 31 May 20247.60m0.50%
Skandia Investment Management ABas of 30 Apr 20241.13m0.07%
FCG Fonder ABas of 31 Dec 2023659.32k0.04%
Storebrand Asset Management ASas of 31 Jan 2024316.72k0.02%
SSgA Funds Management, Inc.as of 05 Jun 2024102.28k0.01%
WBS H�nicke Verm�gensverwaltung GmbHas of 31 Mar 202485.00k0.01%
Danske Bank A/S (Investment Management)as of 31 May 202466.66k0.00%
More ▼
Data from 31 Dec 2022 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.